Replimune Gains FDA Approval Submission After White House Intervention
Replimune (REPL) secured the ability to submit a marketing application for its lead asset RP1, following intervention from White House officials. This marks the third attempt after prior rejections by the FDA.
Tickers: $REPL
Topics: biotech drug approval replimune white house intervention